Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib or Minocycline in Unipolar and Bipolar Depression
NCT06699966Phase 4Not yet recruiting
- Sponsor
- Stony Brook University
- Start
- Jun 2027
- Primary completion
- Jun 2031
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised trial in major depressive disorder (MDD) and bipolar disorder (BD) comparing Celecoxib Arm with Minocycline Arm (2 arms). Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
celecoxibminocycline
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06699966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699966.